Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer

The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET / CT and PET / MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed patients biochemical recurrence after radical treatment

Trial Details

NCT ID
NCT05582876
Phase
NA
Sponsor
Medical University of Bialystok
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Radiopharmaceutical 68Ga-PSMA-11 PET/CT
Locations (sample)
  • Bialystok, Poland|53.13333,23.16433
  • Bialystok, Poland|53.13333,23.16433
  • Bialystok, Poland|53.13333,23.16433
  • Bialystok, Poland|53.13333,23.16433
  • Bydgoszcz, Poland|53.1235,18.00762

Key Eligibility Criteria

  • Group 1. Patients with diagnosis or high probability of medium and high prostate cancer according International Society of Urological Pathology (IS…
  • Prostate adenocarcinoma confirmed by biopsy and histopathological examination
  • Results indicating a moderate RGK (Gleason score 7 or cT2b or PSA 10-20 ng / ml) or high (Gleason score\> 7 or cT2c or PSA\> 20 ng / ml) risk accor…
  • Creatinine value allowing for safe PET / MR examination with a contrast agent: creatinine less than or equal to 1.5 times the upper limit of normal…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →